Skip to main content

Advertisement

Log in

Indications for bone marrow examinations in rheumatology

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Hematologic involvement or hematologic malignancies are frequently encountered during the course of rheumatic diseases. Bone marrow (BM) aspiration and/or biopsy examinations may have a diagnostic role in explaining hematologic findings detected in rheumatology clinical practice. Our aim was to describe the indications for BM examinations and to share our BM aspiration/biopsy results. We analyzed 140 BM aspiration/biopsy results of patients conducted at the Department of Rheumatology from 2010 to 2018. Demographics, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) values, serum biochemistry test results including lactate dehydrogenase (LDH), organomegaly, indications for BM examinations and BM examination results for each patient, and mortality rates were recorded. Out of the 140 patients, 63.6% were female, and the median (Q1–Q3) age was 53 (39.5–65) years. One hundred fifteen (82.1%) patients were diagnosed as having primary rheumatic disease, and 25 (17.8%) were admitted due to musculoskeletal symptoms. Rheumatoid arthritis (RA) (n = 34, [29.5%]), and systemic lupus erythematosus (SLE) (n = 21, [18.2%]) were the most common rheumatic diseases. Cytopenia was the most common indication for BM aspiration/biopsy (n = 83, [59.3%]). Thirty-nine (47%) of 83 patients had drug-induced cytopenia. A pathology was detected in 40 (28.5%) of the 140 BM examinations. Patients with pathologic BM results had either a hematologic malignancy (n = 38, [95%]) or metastasis to a solid organ (n = 2, [5%]). The group of patients with pathologic BM biopsy results had significantly higher rates of lymphadenopathy, splenomegaly, and monoclonal gammopathy compared with the group with non-pathologic results (p = 0.001, p = 0.011, and p = 0.023, respectively). Likewise, LDH concentrations of those with pathologic results were higher than in patients with non-pathologic results [737 (range 577–1420) IU/L vs. 541 (range 306–840) IU/L, p = 0.019]. In this study, cytopenia or CBC abnormalities accompanied by elevated LDH values or anemia along with increased ESR were the most common indications for BM aspiration/biopsy. Further prospective studies are needed to determine the indications of BM aspiration/biopsy and establish the parameters that predict abnormal BM results in rheumatology practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC (2008) ICSH guidelines for the standardizations of bone marrow specimens and reports. Int Jnl Lab Hem 30:349–364

    Article  Google Scholar 

  2. Focosi D (2010) Bone marrow aspiration and biopsy. N Engl J Med 362:182–183

    Article  CAS  PubMed  Google Scholar 

  3. Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy: a review of UK data for 2004. Haematologica 91:1293–1294

    PubMed  Google Scholar 

  4. Garton MJ, Keir G, Dickie A, Steven M, Rennie JA (2006) Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 45:355–356

    Article  CAS  PubMed  Google Scholar 

  5. Loctin A, Bailly F, Laroche D, Tavernier C, Maillefert JF, Ornetti P (2013) Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations. Clin Rheumatol 32:115–121

    Article  PubMed  Google Scholar 

  6. Richter JG, Gossen P, Germing U, Blum S, Hildebrandt B, Braunstein S, Huscher D, Schneider M (2009) Rationale for bone marrow examination in patients with inflammatory rheumatic diseases. Wen Klin Wochenschr 121:690–699

    Article  Google Scholar 

  7. Hunt KE, Salama ME, Sever CE, Foucar K (2013) Bone marrow examination for unexplained cytopenias reveals nonspesific findings patients with collagen vascular disease. Arch Pathol Lab Med 137:948–954

    Article  PubMed  Google Scholar 

  8. Üsküdar Cansu D, Üsküdar Teke H, Işiksoy S, Korkmaz C (2018) Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis. Int J Rheum Dis 21:1049–1059

    Article  CAS  PubMed  Google Scholar 

  9. Papageorgiou A, Ziakas PD, Tzioufas AG, Voulgarelis M (2013) Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations. Clin Exp Rheumatol 31:76–83

    PubMed  Google Scholar 

  10. Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12:259–268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF (2015) A reappraisal of the association between Behçet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol 33(6 Suppl 94):S145–S151

    PubMed  Google Scholar 

  12. Bornstein G, Furie N, Perel N, Ben-Zvi I, Grossman C (2018) Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. Rheumatol Int 38:1743–1749

    Article  CAS  PubMed  Google Scholar 

  13. Kim HA, Kwon JE, Yim H, Suh CH, Jung JY, Han JH (2015) The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Baltimore) 94:e787

    Article  Google Scholar 

  14. Rosenthal NS, Farhi DC (1989) Bone marrow findings in connective tissue disease. Am J Clin Pathol 92:650–654

    Article  CAS  PubMed  Google Scholar 

  15. Curtis BR (2017) Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017:187–193

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

HUT and DUC designed, collected the data and analyzed the results, HUT, DUC and CK wrote the manuscript, critically reviewed the manuscript and wrote the final version. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Döndü Üsküdar Cansu.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was not obtained from the patients since ethics committee did not ask for it in such studies processing medical records anonymously.

Informed consent

Written informed consent was not obtained from the patients since ethics committee did not ask for it in such studies processing medical records anonymously.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teke, H.Ü., Cansu, D.Ü. & Korkmaz, C. Indications for bone marrow examinations in rheumatology. Rheumatol Int 39, 1221–1228 (2019). https://doi.org/10.1007/s00296-019-04312-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-019-04312-w

Keywords

Navigation